These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20463088)

  • 1. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.
    Fakih MG; Fetterly G; Egorin MJ; Muindi JR; Espinoza-Delgado I; Zwiebel JA; Litwin A; Holleran JL; Wang K; Diasio RB
    Clin Cancer Res; 2010 Jul; 16(14):3786-94. PubMed ID: 20463088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.
    Fakih MG; Pendyala L; Fetterly G; Toth K; Zwiebel JA; Espinoza-Delgado I; Litwin A; Rustum YM; Ross ME; Holleran JL; Egorin MJ
    Clin Cancer Res; 2009 May; 15(9):3189-95. PubMed ID: 19383814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer.
    Fakih MG; Groman A; McMahon J; Wilding G; Muindi JR
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):743-51. PubMed ID: 22020318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.
    Wilson PM; El-Khoueiry A; Iqbal S; Fazzone W; LaBonte MJ; Groshen S; Yang D; Danenberg KD; Cole S; Kornacki M; Ladner RD; Lenz HJ
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):979-88. PubMed ID: 20062993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
    Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
    Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
    Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
    Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
    Starling N; Vázquez-Mazón F; Cunningham D; Chau I; Tabernero J; Ramos FJ; Iveson TJ; Saunders MP; Aranda E; Countouriotis AM; Ruiz-Garcia A; Wei G; Tursi JM; Guillen-Ponce C; Carrato A
    Ann Oncol; 2012 Jan; 23(1):119-127. PubMed ID: 21447616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
    Meyerhardt JA; Clark JW; Supko JG; Eder JP; Ogino S; Stewart CF; D'Amato F; Dancey J; Enzinger PC; Zhu AX; Ryan DP; Earle CC; Mayer RJ; Michelini A; Kinsella K; Fuchs CS
    Cancer Chemother Pharmacol; 2007 Oct; 60(5):661-70. PubMed ID: 17216531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
    Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
    J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
    Messersmith WA; Laheru DA; Senzer NN; Donehower RC; Grouleff P; Rogers T; Kelley SK; Ramies DA; Lum BL; Hidalgo M
    Clin Cancer Res; 2004 Oct; 10(19):6522-7. PubMed ID: 15475439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
    Fouladi M; Park JR; Stewart CF; Gilbertson RJ; Schaiquevich P; Sun J; Reid JM; Ames MM; Speights R; Ingle AM; Zwiebel J; Blaney SM; Adamson PC
    J Clin Oncol; 2010 Aug; 28(22):3623-9. PubMed ID: 20606092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study.
    Ji D; Shen W; Li T; Wang H; Bai J; Cao J; Hu X
    Invest New Drugs; 2024 Aug; 42(4):462-470. PubMed ID: 39037543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
    Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
    Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-in-human phase I study of infusional and bolus schedules of Deflexifol, a novel 5-fluorouracil and leucovorin formulation, after failure of standard treatment.
    Clingan PR; Ackland SP; Brungs D; de Souza P; Aghmesheh M; Garg MB; Ranson RD; Parker S; Jokela R; Ranson M
    Asia Pac J Clin Oncol; 2019 Jun; 15(3):151-157. PubMed ID: 30843362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
    Schelman WR; Traynor AM; Holen KD; Kolesar JM; Attia S; Hoang T; Eickhoff J; Jiang Z; Alberti D; Marnocha R; Reid JM; Ames MM; McGovern RM; Espinoza-Delgado I; Wright JJ; Wilding G; Bailey HH
    Invest New Drugs; 2013 Dec; 31(6):1539-46. PubMed ID: 24114121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
    Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM
    Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
    Siegel-Lakhai WS; Beijnen JH; Vervenne WL; Boot H; Keessen M; Versola M; Koch KM; Smith DA; Pandite L; Richel DJ; Schellens JH
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4495-502. PubMed ID: 17671135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors.
    Chiang NJ; Chao TY; Hsieh RK; Wang CH; Wang YW; Yeh CG; Chen LT
    BMC Cancer; 2016 Nov; 16(1):907. PubMed ID: 27871319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
    Hanauske AR; Cassidy J; Sastre J; Bolling C; Jones RJ; Rakhit A; Fettner S; Brennscheidt U; Feyereislova A; Díaz-Rubio E
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):523-31. PubMed ID: 17255274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer.
    Kelsen DP; Saltz L; Cohen AM; Yao TJ; Enker W; Tong W; Tao Y; Bertino JR
    Cancer; 1994 Oct; 74(8):2224-33. PubMed ID: 7922973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.